Skip to main content
. 2019 Jun 19;2(2):356–364. doi: 10.20517/cdr.2018.004

Figure 1.

Figure 1

Pathways inhibited by CB-839, nivolumab, cabozantinib and everolimus. GLS: glutaminase; GSH: glutathione; ATP: adenosine triphosphate; αKG: alpha-ketoglutarate; PD-1: programmed death receptor 1; PD-L1: programmed death ligand 1